Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma.
GRP78/BiP
TS
TUBB3
Topo-II
VEGFR2
drug sensitivity
immunohistochemistry
lung
pleomorphic carcinoma
stathmin 1
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Oct 2019
24 Oct 2019
Historique:
received:
14
10
2019
accepted:
22
10
2019
entrez:
27
10
2019
pubmed:
28
10
2019
medline:
28
10
2019
Statut:
epublish
Résumé
Various drug-sensitivity markers are potentially responsible for tumor progression and chemotherapy resistance in cancer patients with both epithelial and sarcomatous components; however, the clinicopathological significance of drug-sensitivity markers in patients with pulmonary pleomorphic carcinoma (PPC) remains unknown. Here, we clarified the prognostic impact of these drug-sensitivity markers in PPC by performing immunohistochemical and clinicopathologic analyses of samples from 105 patients with surgically resected PPC in order to evaluate levels of vascular endothelial growth factor 2 (VEGFR2), stathmin 1 (STMN1), tubulin β3 class III (TUBB3), thymidylate synthetase (TS), topoisomerase II (Topo-II), glucose-regulated protein, and 78 kDa (GRP78)/binding immunoglobulin protein (BiP). We observed the rates of high expression for VEGFR2, STMN1, TUBB3, TS, Topo-II, and GRP78/BiP were 33% (39/105), 35% (37/105), 61% (64/105), 51% (53/105), 31% (33/105), and 51% (53/105) of the samples, respectively. Moreover, multivariate analysis identified VEGFR2 and GRP78/BiP as significant independent markers for predicting worse prognosis. These findings suggested elevated VEGFR2 and decreased GRP78/BiP levels as independent factors for predicting poor outcomes following surgical resection in patients with PPC.
Identifiants
pubmed: 31653009
pii: cancers11111636
doi: 10.3390/cancers11111636
pmc: PMC6895922
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 1996 Apr;14(4):1048-54
pubmed: 8648356
J Clin Pathol. 2004 Jun;57(6):591-7
pubmed: 15166262
Cancer. 1994 Jun 15;73(12):2936-45
pubmed: 8199991
J Clin Oncol. 2015 May 20;33(15):1680-7
pubmed: 25897160
Curr Opin Oncol. 2006 Mar;18(2):151-5
pubmed: 16462184
Lung Cancer. 2018 Jan;115:42-48
pubmed: 29290260
Cell. 1996 Feb 23;84(4):623-31
pubmed: 8598048
Br J Cancer. 2006 Sep 4;95(5):607-15
pubmed: 16880781
J Thorac Oncol. 2010 Apr;5(4):460-5
pubmed: 20107421
Lung Cancer. 2006 Jul;53(1):91-6
pubmed: 16697074
Mt Sinai J Med. 2004 Oct;71(5):289-97
pubmed: 15543429
Breast Cancer Res Treat. 1999 Mar;54(2):135-46
pubmed: 10424404
Int J Cancer. 2012 Aug 15;131(4):E362-70
pubmed: 21953091
Lung Cancer. 2005 Jul;49(1):55-62
pubmed: 15949590
Biochim Biophys Acta. 1977 Dec 23;473(2):73-92
pubmed: 145246
Bull Cancer. 2005 Feb;92(2):E25-30
pubmed: 15749640
Cancer Res. 2000 Jun 1;60(11):3088-95
pubmed: 10850461
Lung Cancer. 2007 Oct;58(1):112-5
pubmed: 17574296
Folia Histochem Cytobiol. 2001;39 Suppl 2:100-1
pubmed: 11820558
Lung Cancer. 2010 Feb;67(2):136-43
pubmed: 19828208
Am J Clin Pathol. 2009 Apr;131(4):478-89
pubmed: 19289583
Curr Mol Med. 2006 Feb;6(1):45-54
pubmed: 16472112
N Engl J Med. 2007 Feb 22;356(8):800-8
pubmed: 17314339
Lung Cancer. 2004 Feb;43(2):145-9
pubmed: 14739034
Carcinogenesis. 2013 Oct;34(10):2314-21
pubmed: 23749771
Lung Cancer. 2011 Feb;71(2):144-50
pubmed: 20646779
Int J Clin Oncol. 2013 Jun;18(3):371-9
pubmed: 22358390
Cancer. 2009 Apr 15;115(8):1701-12
pubmed: 19197998
Hum Pathol. 2019 Feb;84:142-149
pubmed: 30300664
J Cell Sci. 1998 Nov;111 ( Pt 22):3333-46
pubmed: 9788875
J Thorac Oncol. 2008 Jun;3(6):583-9
pubmed: 18520795
Int J Clin Oncol. 2017 Oct;22(5):872-879
pubmed: 28550415
Nat Rev Cancer. 2004 Apr;4(4):253-65
pubmed: 15057285
Lung Cancer. 2009 Dec;66(3):314-8
pubmed: 19324448
Mod Pathol. 1998 Feb;11(2):155-68
pubmed: 9504686
Med Oncol. 2012 Sep;29(3):1663-72
pubmed: 21948461
Lung Cancer. 2001 Oct;34(1):91-7
pubmed: 11557118